Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study.

CONCLUSIONS: Our real-life experience suggests that all intermediate-risk ER+/HER2-eBC patients who are initially deemed candidates for CHT should be tested with the 21-gene test. The potential to spare CT in at least half of them offers relevant advantages for patients and national health services.
PMID: 32325372 [PubMed - as supplied by publisher]

Source: Breast - April 14, 2020 Category: Cancer & Oncology Authors: Zambelli A, Simoncini E, Giordano M, Laverde N, Farina G, Torri V, Colombo G, Piacentini G, Fotia V, Vassalli L, Pugliese P, Poletti P, Caremoli ER, Tondini C Tags: Breast Source Type: research